The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.
Published: 13 Nov 2025
Citation: Akanil Fener N, Koç AS, Seyhan EC. Association of histopathologic parameters with angiogenesis and endoglin in laryngeal squamous cell carcinoma. J Curr Hematol Oncol Res. 2025;3(4):77-81.
Published: 13 Nov 2025
Citation: Sabando B, Quinonez J, Orquera A, et al. Adults philadelphia-positive B–acute lymphoblastic leukemia in a moderate Health Access and Quality Index country. J Curr Hematol Oncol Res. 2025;3(4):82-89.
Published: 13 Nov 2025
Citation: Yapıcı O, Merdin A. Evaluation of public awareness and attitudes on Crimean-Congo hemorrhagic fever: a survey study in a rural area of western Anatolia of Turkiye. J Curr Hematol Oncol Res. 2025;3(4):90-93.
Published: 13 Nov 2025
Citation: Altahhan V, Öner Soy H, Koç Tiske P. Cancer stem cells. J Curr Hematol Oncol Res. 2025;3(4):94-99.
Published: 13 Nov 2025
Citation: Candar Ö, Ekinci Ö, Merter M, Aslan M, Çalık İ. Isolated myeloid sarcoma causing obstructive jaundice in duodenal ampulla: a very rare case. J Curr Hematol Oncol Res. 2025;3(4):100-102.
Published: 13 Nov 2025
Citation: Shahab S, Selim C, Çiftçiler R. A rare disease: primary bone lymphoma case report. J Curr Hematol Oncol Res. 2025;3(4):103-105.
Published: 30 Aug 2023
Citation: Barış Iİ, Büyükbayram H. ß-catenin expression in myelodysplastic syndromes and myeloproliferative neoplasms in bone marrow, in relation to CD34 and CD117 status. J Curr Hematol Oncol Res. 2023;1(3):54-58.
Published: 26 Feb 2023
Citation: Kaya A, Berber İ, Kuku İ, et al. Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID-19 antibody level in hematological patients. J Curr Hematol Oncol Res. 2023; 1(1): 1-4
Published: 12 Feb 2024
Citation: Çelik S, Kaynar L. Get two with one: bevacizumab treatment in hereditary hemorrhagic telangiectasia with concomitant cirrhosis. J Curr Hematol Oncol Res. 2023; 1(1): 15-17.